Porphyria
Porphyria
Updated: 02/09/2021
© Jun Wang, MD, PhD
General features
- Non-inflammatory blistering disorder
- Autosomal dominant except congenital erythropoietic porphyria (autosomal recessive)
- Various systemic involvement and clinical presentation
- Acute and chronic forms
- Subepidermal vesicles as skin manifestation
Pathogenesis
- Disturbance of porphyrin metabolism
- Accumulation and increased excretion of porphyrins and precursors
Acute intermittent porphyria
- Autosomal dominant
- Defects in porphobilinogen-deaminase
- Accumulation of porphobilinogen and amino-levulinic acid
- More common in women
- Commonly become symptomatic around 18-40
- Most commonly presents with neurologic dysfunctions
- Peripheral and autonomic neuropathies
- Psychiatric presentations: Depression most common
- Seizures, delirium, cortical blindness, coma, etc
- Other clinical presentations
- Abdominal pain: commonly epigastric colicky pain
- Constipation
- Usually DO NOT have skin rash
- Diagnosis: Urine porphobilinogen > 6 mg/L during an acute attack
- Management
- Aim at reduce heme synthesis and production of porphyrin precursors:
- High dose glucose
- Hematin: once started, do not need glucose
- Pain control
- Other symptomatic treatments
- Most common type
- Familial or acquired
- Uroporphyrinogen decarboxylase deficiency
- Autosomal dominant if familial, due to mutation of UROD gene
- Rarely due to congenital susceptibility of UROD inhibition, with normal gene, in acquired form
- Clinical presentations more common in adults
- Clinical presentations usually occurs after abnormal liver functions due to alcohol, hemochromatosis, viral infection, estrogen or other environmental factors
- Clinical presentations
- Most common: Skin fragility and blistering, especially sun exposed areas
- Hypertrichosis
- Melasma like hyperpigmentation
- Urine discoloration
- Digital shortening, atrophy, and contractures in severe cases
- Diagnosis
- Suspected in adults with blistering lesions on sun-exposed skin
- No neurovisceral symptoms
- Screening test: Total porphyrin, if normal, no porphyrin
- Plasma and urine porphyrins levels
- Uroporphyrinogen decarboxylase activity assay
- Molecular analysis for UROD
- Management
- Sun light avoidance
- Cessation of alcohol, tobacco, etc
- Adjust estrogen therapy if needed
- Other management focused on underlying disorders, such as hemochromatosis
- Hydroxychloroquine or chloroquine
Back to contents
Comments
Post a Comment